Effects of High-Dose Rosuvastatin on Ventricular Remodelling and Cardiac Function in ST-Segment Elevation Myocardial Infarction

References

• WuHB, TianHP, WangXC, et al. Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. Am J Transl Res. 2018;10(7):2175–2183.30093954
   PubMed Web of Science ®Google Scholar
• ZimmermannS, FlachskampfFA, AlffA. Out-of-hospital cardiac arrest and percutaneous coronary intervention for ST-elevation myocardial infarction: long-term survival and neurological outcome. Int J Cardiol. 2013;166(1):236.22204846
   PubMed Web of Science ®Google Scholar
• ShahN, KellyAM, CoxN, et al. Myocardial Infarction in the “Young”: risk Factors, Presentation, Management and Prognosis. Heart Lung Circ. 2016;25(10):955–960.27265644
   PubMed Web of Science ®Google Scholar
• BhattAS, AmbrosyAP, VelazquezEJ. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep. 2017;19(8):71.28660552
   PubMed Web of Science ®Google Scholar
• HofmannU, FrantzS. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res. 2015;116(2):354–367.25593279
   PubMed Web of Science ®Google Scholar
• ChouR, DanaT, BlazinaI, et al. Statins for Prevention of Cardiovascular Disease in Adults: evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–2024.27838722
   PubMed Web of Science ®Google Scholar
• OesterleA, LaufsU, LiaoJK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017;120(1):229–243.28057795
   PubMed Web of Science ®Google Scholar
• ReddyR, ChahoudG, MehtaJL. Modulation of cardiovascular remodeling with statins: fact or fiction? Curr Vasc Pharmacol. 2005;3(1):69–79.15638784
   PubMedGoogle Scholar
• RidkerPM, DanielsonE, FonsecaFA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.18997196
   PubMed Web of Science ®Google Scholar
• BaoJW, SunB, MaPP, et al. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci. 2018;22(1):238–245.29364492
   PubMed Web of Science ®Google Scholar
• TaylorJ. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2506–2507.23065972
   PubMed Web of Science ®Google Scholar
• BanningAP, BaumbachA, BlackmanD, et al. Percutaneous coronary intervention in the UK: recommendations for good practice 2015. Heart. 2015;101(Suppl 3):1–13.26041756
   PubMed Web of Science ®Google Scholar
• StegPG, JamesSK, AtarD, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.22922416
   PubMed Web of Science ®Google Scholar
• FrangogiannisNG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841–1875.26426469
   PubMed Web of Science ®Google Scholar
• ReedGW, RossiJE, CannonCP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210.27502078
   PubMed Web of Science ®Google Scholar
• AdhyaruBB, JacobsonTA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15(12):757–769.30375494
   PubMed Web of Science ®Google Scholar
• WangX, ZhaoX, LiL, et al. Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease. Heart Lung Circ. 2016;25(5):459–465.26687339
   PubMed Web of Science ®Google Scholar
• KonesR. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325–380.
   PubMed Web of Science ®Google Scholar
• HolmesMV, MillwoodIY, KartsonakiC, et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol. 2018;71(6):620–632.29420958
   PubMed Web of Science ®Google Scholar
• WinterMP, WiesbauerF, BlessbergerH, et al. Lipid profile and long-term outcome in premature myocardial infarction. Eur J Clin Invest. 2018;48(10):e13008.30062727
   PubMed Web of Science ®Google Scholar
• NishikidoT, OyamaJ, KeidaT, et al. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: the Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. J Cardiol. 2016;67(4):340–346.26162946
   PubMed Web of Science ®Google Scholar
• PaulS, JellingerM, HandelsmanY, et al. American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl 2):1–87.
   Google Scholar
• TosoA, LeonciniM, MaioliM, et al. Relationship Between Inflammation and Benefits of Early High-Dose Rosuvastatin on Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome: the Pathophysiological Link in the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). JACC Cardiovasc Interv. 2014;7(12):1421–1429.25523533
   PubMed Web of Science ®Google Scholar
• GoliaE, LimongelliG, NataleF, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16(9):435.25037581
   PubMed Web of Science ®Google Scholar
• PavlovićM, ApostolovićS, StokanovićD, et al. The Association between Galectin-3 and hs-CRP and the Clinical Outcome after Non-ST-Elevation Myocardial Infarction with Preexisting Atrial Fibrillation. Sci Rep. 2017;7(1):15106.29118378
   PubMed Web of Science ®Google Scholar
• ZhangY, ShaoT, YaoL, et al. Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction. Exp Ther Med. 2018;16(4):3383–3388.30233685
   PubMed Web of Science ®Google Scholar
• InoueT, KatoT, UchidaT, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005;46(2):239–245.16022949
   PubMed Web of Science ®Google Scholar
• RidkerPM, LüscherTF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–1791.24864079
   PubMed Web of Science ®Google Scholar
• CenW, ChenZ, GuN, et al. Prevention of AMI Induced Ventricular Remodeling: inhibitory Effects of Heart-Protecting Musk Pill on IL-6 and TNF-Alpha. Evid Based Complement Alternat Med. 2017;2017:3217395.28373886
   PubMed Web of Science ®Google Scholar
• LacerdaL, SomersS, OpieLH, et al. Ischaemic Postconditioning Protects Against Reperfusion Injury via the SAFE. Pathway Cardiovasc Res. 2009;84(2):201–208.19666677
   PubMed Web of Science ®Google Scholar
• PadróT, CubedoJ, CaminoS, et al. Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs. J Am Coll Cardiol. 2017;70(2):165–178.28683964
   PubMed Web of Science ®Google Scholar
• BensonV, McMahonAC, LoweHC. ICAM-1 in acute myocardial infarction: a potential therapeutic target. Curr Mol Med. 2007;7(2):219–227.17346172
   PubMed Web of Science ®Google Scholar
• LawsonC, WolfS. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22–32.19307690
   PubMed Web of Science ®Google Scholar
• IyerRP, JungM, LindseyML. MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol. 2016;311(1):H190–H198.27208160
   PubMed Web of Science ®Google Scholar
• NagaseH, VisseR, MurphyG. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–573.16405877
   PubMed Web of Science ®Google Scholar
• ZavadzkasJA, StroudRE, BougesS, et al. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014;114(9):1435–1445.24637197
   PubMed Web of Science ®Google Scholar
• SpinaleFG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87(4):1285–1342.17928585
   PubMed Web of Science ®Google Scholar
• ChenYS, GiWT, LiaoTY, et al. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med. 2016;10(3):329–342.26860036
   PubMed Web of Science ®Google Scholar
• LiM, YuanY, GuoK, et al. Value of Galectin-3 in Acute Myocardial Infarction. Am J Cardiovasc Drugs. 2019;1:245.
   Google Scholar
• MariesL, ManitiuI. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013;24(7):286–289.24217307
   PubMed Web of Science ®Google Scholar
• van KimmenadeRR, BakkerJA, CrijnsHJ, et al. The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure. Neth Heart J. 2004;12(2):61–63.25696296
   PubMedGoogle Scholar